000756.SZ
000756.SZ
CNE000000BG1
XINHUA PHARM
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 80/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±53.4% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (-0.0x).

Beta (Market Relation)
-0.05x
Defensive
Volatility (5Y p.a.)
53.4% p.a.
5-Year Horizon
Max Drawdown (5Y)
-74.1%
5-Year Horizon
Sharpe Ratio
0.20
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — -5.5%
3 Years 40.4% -51.2% -0.28 -8.7%
5 Years 53.4% -74.1% 0.2 +13.2%
10 Years 45.8% -74.1% 0.03 +3.9%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 47.8 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (53.4% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -74.1% in the extended horizon.
ende